KITLG and neoplasm: Meanwhile, tyrosine kinase inhibitors (TKIs) can select appropriate targets, such as vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor (PDGFR), and stem cell factor (SCF) receptor/c-kit, to block tumor-related signaling pathways, normalize the vascularization, and improve the oxygenation in tumor [8–10].